The aim of the project is to collect and evaluate data from real clinical practice, which are related to the administration of CAR-T cell therapy in patients with certain hematological malignancies who face poor prognosis. CAR-T cell therapy is currently indicated in adult patients with certain types of non-Hodgkin's lymphoma, incl. aggressive, relapsing or refractory diffuse large B-cell lymphoma, primary mediastinal B-lymphoma, high-grade B-lymphoma, transformed follicular lymphoma and mantle cell lymphoma; and in pediatric patients and patients under 25 years of age with acute lymphoblastic leukemia (B-ALL) who do not respond to a defined number of standard therapy lines.
start of the project: January 2021
Monitoring the number of treated patients for an overview of the current situation and discussion with health care payers. Evaluation of the risk-benefit balance in assessing the indication and for optimizing the process of selecting patients for treatment with CAR-T cell therapy.
The guarantor of the register is MUDr. Frantisek Folber, Ph.D. (University Hospital Brno Department of Internal Hematology and Oncology).
Project management is provided by the Institute of Biostatistics and Analyzes, s.r.o., a spin-off company of Masaryk University.
Michal jetelina, Project Manager
Petr Brabec, Executive Officer